Two Cardiovascular Trial Hits Get Merck & Co.’s Blood Pumping
Sotatercept And MK-0616 Both Blockbuster-Tipped
Executive Summary
Merck has taken two important steps towards its goal of achieving eight new cardiovascular drug approvals by 2030, presenting promising data for two potential blockbusters at the ACC meeting.